The Safety Evaluation Of Coronary Artery Bypass Grafting In Patients With Preoperative Application Tirofiban

Objective To evaluate the safety of of coronaryartery bypass grafting in patients with preoperative application tirofiban MethodsⅠrandomly selected hospital on October 1,2007 2008 April 1 of a total of 40 cases of patients with coronary heart disease by coronary angiography confirmed the three serious vascular lesions are not suitable medical intervention therapy need surgery bypass treatment.Anti-platelet drugs based on the pharmacological effects,in order to reduce bleeding out of preoperative aspirin,clopidogrel 5-7 days,and low-molecular-weight heparin anticoagulation alone. Therefore,an increase of elective surgery before the vicious incident occurred cardiovascular risk.Twenty patients with ACS standard treatment after recurrent ischemic events such as unstable angina patients as a group.20 cases of the ACS after standard treatment with the above symptoms can be controlled with a control group.The two groups in age,gender,ethnic and other risk factors,such as complications no difference.To the Observer Group in elective surgery during extended to the highest nitrates,B-receptor blockers inhibit myocardial remodeling,such as statin lipid treatment given on the basis of tirofiban hydrochloride(Xinweining,Wuhan lofty pharmaceutical Group production batches H20041165) in the treatment,the initial 30-minute infusion rate of 0.4 ug / minkg,and then to 0.1 ug / Trace minkg by continuous intravenous infusion pump 24-72 hours,with 24 hours before the operation to stop.Two cases were in the entire downlink beating Ma-pump coronary artery bypass surgery.To the Observer Group in the number of platelets before and after treatment, hematocrit,blood red eggs of a comparative analysis.On the two patients before prothrombin time,activated partial thromboplastin time of the adoption,as well as autologous blood transfusion machine accurate records of the amount of bleeding were analyzed.Results the number of platelets before and after treatment there were no significant differences,after the administration did not cause platelet number of significantly reduced.And hematocrit,blood red eggs before and after the administration of contrast analyzed P＜0.005,a significant difference,after treatment hematocrit,blood red eggs than before treatment has declined.Two preoperative prothrombin time, activated partial thromboplastin time,during autologous blood transfusion in surgery measured at the beginning of ACT,ACT 2 hours by the change of statistical analysis that P＞0.05,no significant difference.Conclusion In elective coronary artery bypass graft surgery in patients with the use of tirofiban hydrochloride significant improvement in patients with clinical symptoms of the operation did not increase bleeding risk.